Abstract:Unlike the arginyl‐tRNA synthetases (ArgRSs) reported previously, leishmanial ArgRS activates L‐Arg in the absence of its cognate tRNA. Deletion of the unique insertion region within its active site led to a loss of tRNA binding capability and an alteration in its catalytic and structural features along with modification of inhibition modality by a benzothiazolo‐coumarin derivative. Here, we present a detailed characterization of a new form of ArgRS that can be employed for developing novel anti‐leishmanial agents. Aminoacylation by tRNA synthetase is a crucial part of protein synthesis and is widely recognized as a therapeutic target for drug development. Unlike the arginyl‐tRNA synthetases (ArgRSs) reported previously, here, we report an ArgRS of Leishmania donovani (LdArgRS) that can follow the canonical two‐step aminoacylation process. Since a previously uncharacterized insertion region is present within its catalytic domain, we implemented the splicing by overlap extension PCR (SOE–PCR) method to create a deletion mutant (ΔIns‐LdArgRS) devoid of this region to investigate its function. Notably, the purified LdArgRS and ΔIns‐LdArgRS exhibited different oligomeric states along with variations in their enzymatic activity. The full‐length protein showed better catalytic efficiency than ΔIns‐LdArgRS, and the insertion region was identified as the tRNA binding domain. In addition, a benzothiazolo‐coumarin derivative (Comp‐7j) possessing high pharmacokinetic properties was recognized as a competitive and more specific inhibitor of LdArgRS than its human counterpart. Removal of the insertion region altered the mode of inhibition for ΔIns‐LdArgRS and caused a reduction in the inhibitor's binding affinity. Both purified proteins depicted variances in the secondary structural content upon ligand binding and thus, thermostability. Apart from the trypanosomatid‐specific insertion and Rossmann fold motif, LdArgRS revealed typical structural characteristics of ArgRSs, and Comp‐7j was found to bind within the ATP binding pocket. Furthermore, the placement of tRNAArg near the insertion region enhanced the stability and compactness of LdArgRS compared to other ligands. This study thus reports a unique ArgRS with respect to catalytic as well as structural properties, which can be considered a plausible drug target for the derivation of novel anti‐leishmanial agents.

An Antifungal Agent Inhibits an Aminoacyl-tRNA Synthetase by Trapping tRNA in the Editing Site

Research Advances of Aminoacyl-tRNA Synthetase Inhibitors As Novel Anti-infective Agents

Synthesis and Biological Evaluation of 1,3-Dideazapurine-Like 7-Amino-5-Hydroxymethyl-Benzimidazole Ribonucleoside Analogues as Aminoacyl-tRNA Synthetase Inhibitors

Aminoacyl-tRNA synthetase inhibitors as potent antibacterials.

Structural Basis for Full-Spectrum Inhibition of Translational Functions on a Trna Synthetase

[New Inhibitors Targeting Bacterial RNA Polymerase].

Inhibition of Plasmodium falciparum Lysyl-tRNA synthetase via an anaplastic lymphoma kinase inhibitor

Family-wide analysis of aminoacyl-sulfamoyl-3-deazaadenosine analogues as inhibitors of aminoacyl-tRNA synthetases

A Novel Antibiotic Mechanism of l-Cyclopropylalanine Blocking the Biosynthetic Pathway of Essential Amino Acid l-Leucine

Insights into the Effects of Ligand Binding on Leucyl-tRNA Synthetase Inhibitors for Tuberculosis: In Silico Analysis and Isothermal Titration Calorimetry Validation

4-Alkoxy-3-arylfuran-2(5h)-ones As Inhibitors of Tyrosyl-Trna Synthetase: Synthesis, Molecular Docking and Antibacterial Evaluation.

Reaction hijacking of tyrosine tRNA synthetase as a new whole-of-life-cycle antimalarial strategy

Aminoacyl-tRNA synthetase dependent angiogenesis revealed by a bioengineered macrolide inhibitor

Unraveling the peculiarities and development of novel inhibitors of leishmanial arginyl‐tRNA synthetase

tRNA hypomodification facilitates 5-fluorocytosine resistance via cross-pathway control system activation in .

Fluoropyrimidines trigger decay of hypomodified tRNA in yeast

Fragment-based discovery of a new class of inhibitors targeting mycobacterial tRNA modification

Modifications of Aminoglycoside Antibiotics Targeting RNA

Natural Trojan horse inhibitors of aminoacyl-tRNA synthetases

In Silico Discovery of Aminoacyl-tRNA Synthetase Inhibitors

Design and testing of selective inactivators against an antifungal enzyme target